(Press-News.org) Peer reviewed – Experimental study – Human DNA
Scientists at the University of East Anglia and Oxford Biodynamics have developed a high accuracy blood test to diagnose Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (ME/CFS).
The debilitating long-term illness affects millions worldwide - including over 400,000 sufferers in the UK - but is poorly understood and has long lacked reliable diagnostic tools.
With 96 per cent accuracy, the test offers new hope for those living with the condition - which is often misunderstood and misdiagnosed.
And it is hoped that the breakthrough could pave the way for a similar blood test to diagnose long Covid.
Lead researcher Prof Dmitry Pshezhetskiy, from UEA's Norwich Medical School, said: “ME/CFS is a serious and often disabling illness characterised by extreme fatigue that is not relieved by rest.
“We know that some patients report being ignored or even told that their illness is ‘all in their head’.
“With no definitive tests, many patients have gone undiagnosed or misdiagnosed for years.
“We wanted to see if we could develop a blood test to diagnose the condition – and we did!
“Our discovery offers the potential for a simple, accurate blood test to help confirm a diagnosis, which could lead to earlier support and more effective management.”
"Post-Covid syndrome, commonly referred to as long Covid, is one example of ME/CFS, where a similar cluster of symptoms is triggered by the Covid-19 virus, rather than by other known causes such as glandular fever. We therefore hope that our research will also help pave the way for a similar test to accurately diagnose long Covid.”
How the discovery was made
The team used advanced EpiSwitch® 3D Genomics technology from Oxford BioDynamics (AIM:OBD) to see how DNA is folded in blood samples from 47 patients with severe ME/CFS and 61 healthy controls.
Each of our cells contains about two metres of DNA, packed tightly and folded in 3D. These folds aren’t random - millions of them are deliberate, forming a hidden code that helps turn genes on or off to keep us healthy.
OBD Chief Scientific Officer, Alexandre Akoulitchev, said: “Chronic Fatigue Syndrome is not a genetic disease you’re born with. That’s why using EpiSwitch ‘epigenetic’ markers - which can change during a person’s life, unlike fixed genetic code - was key to reaching this high level of accuracy.
“The EpiSwitch platform behind this test, together with OBD’s vast 3D Genomic knowledgebase, has already been proven to deliver practical, rapid blood diagnostics accessible at scale.
“With this breakthrough, we are proud to enable a first-in-class test that can address an unmet need for a quick and reliable diagnostic for a complex, challenging-to-identify illness.”
This approach using EpiSwitch has previously shown success in identifying disease-specific blood markers in highly complex inflammatory and neurological conditions such as fast ALS (amyotrophic lateral sclerosis), rheumatoid arthritis, and certain cancers. This includes the EpiSwitch PSE test, which is a blood test with world-leading accuracy for prostate cancer already used in the UK and US.
The team discovered a unique pattern that appears consistently in people with ME/CFS that is not seen in healthy people.
Using a different approach, this work looked beyond the linear DNA sequence investigated by a previously published DecodeME study, the largest genetic investigation of ME/CFS to date‡.
By examining 3D genomic folds, UEA and Oxford BioDynamics revealed hundreds of additional changes, including five of the eight sites identified by DecodeME, which can now provide a deeper understanding of the disease.
The analysis showed remarkable accuracy – with 92 per cent sensitivity in identifying ME/CFS, which indicates how well the test identifies those who have the disease (a show of true positives) and 98 per cent specificity, which indicates how well it identifies those who do not have the disease.
The researchers also found signs of immune system and inflammation pathways involved in the disease, which may help guide future treatments and identify patients more likely to respond to specific therapies.
A vital tool for diagnosis and treatment
“This is a significant step forward,” said UEA’s Prof Pshezhetskiy. “For the first time, we have a simple blood test that can reliably identify ME/CFS - potentially transforming how we diagnose and manage this complex disease.”
“Additionally, understanding the biological pathways involved in ME/CFS opens the door to developing targeted treatments and identifying which patients might benefit most from specific therapies.
“We hope that the Episwitch® CFS test could become a vital tool in clinical settings, paving the way for more personalised and effective care.”
This research was led by UEA and Oxford BioDynamics in collaboration with The London School of Hygiene & Tropical Medicine and Royal Cornwall Hospitals NHS Trust.
‘Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling’ is published in the Journal of Translational Medicine.
END
Revolutionary blood test for ME / Chronic Fatigue unveiled
2025-10-08
ELSE PRESS RELEASES FROM THIS DATE:
Calorie labelling linked to 2% average reduction in energy content of menu items
2025-10-07
Calorie labelling, which became law in April 2022 in England, is associated with only a small (2%) average reduction in the energy content of food that is available away from home, finds research published in the open access journal BMJ Public Health.
And these changes are primarily due to swapping in slightly lower calorie items, rather than reformulating existing ones, with no changes observed in continuously available items. The impact on population health is likely to be “moderate to limited,” conclude the researchers.
Eating at restaurants, fast food outlets, and ordering takeaways, collectively known as out-of-home food outlets, is common and associated with ...
Widely prescribed opioid painkiller tramadol not that effective for easing chronic pain
2025-10-07
The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine.
And it likely increases the risk of serious side effects, including heart disease, the findings indicate, prompting the researchers to conclude that the potential harms of tramadol probably outweigh its benefits, and that its use should be minimised.
Tramadol is a dual action opioid widely prescribed for the treatment of moderate ...
Exercise snacks may boost cardiorespiratory fitness of physically inactive adults
2025-10-07
Exercise snacks—intentional short bursts of physical activity—may be an effective way of boosting the cardiorespiratory fitness of physically inactive adults, finds a synthesis of the available research, published online in the British Journal of Sports Medicine.
Adherence to exercise snacking throughout the day was high, the findings indicate, and this approach could counter perceived lack of time and low motivation—frequently cited barriers to fulfilling the recommended weekly quota of physical activity for health—say the researchers.
Globally, ...
15,000 women a year with breast cancer could benefit from whole genome sequencing, say researchers
2025-10-07
Whole genome sequencing offered to breast cancer patients is likely to identify unique genetic features that could either guide immediate treatment or help match patients to clinical trials for over 15,000 women a year, say scientists at the University of Cambridge.
In 2022, 2.3 million women were diagnosed with breast cancer worldwide and there were 670,000 related deaths. Despite significant progress in recent years, it remains challenging to accurately identify the best treatments for individual patients and to predict cases with poorer prognosis.
Whole genome sequencing ...
Study highlights risks of Caesarean births to future pregnancies
2025-10-07
Women who have Caesarean births at an advanced stage of labour are about eight times more likely to develop scars in the womb which are known to increase the likelihood of premature births in future pregnancies, UCL researchers have found.
The study, published in the American Journal of Obstetrics & Gynecology, looked at how the stage of labour when the operation is performed affects where the scar forms and how well it heals. More than 40 per cent of all births in high-income countries including England are now by Caesarean.
As labour progresses, ...
GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds
2025-10-07
(Barcelona, Spain, Wednesday 8 September 2025) The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.1
GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the United States between 2019 and 2023.² These medications alter glucose metabolism, gastric motility and sympathetic tone, which may lead to unique uptake patterns on PET-CT. Previous case reports have shown increased FDG uptake in skeletal ...
Scripps Research scientists unlock new patterns of protein behavior in cell membranes
2025-10-07
LA JOLLA, CA— Cellular membrane proteins play many important roles throughout the body, including transporting substances in and out of the cell, transmitting signals, speeding up reactions and helping neighboring cells stick together. When they malfunction, it can cause serious diseases including cancer, making them attractive drug targets. But understanding how membrane proteins behave and function can be challenging because their position within the cell’s lipid membrane—a tightly-packed double layer of fat-like molecules—makes them difficult to study.
Now, Scripps Research ...
Panama Canal may face frequent extreme water lows in coming decades
2025-10-07
WASHINGTON — In 2023, Panama experienced one of the worst droughts in its recorded history, and it severely depleted water available to the Panama Canal, so much that it decreased shipping by 30%. A new study projected that those historic water lows could become the new norm if greenhouse gas emissions continue to rise.
“If we mitigate emissions and we choose one of the lower emissions pathways, then it really keeps this system pretty stable,” said Samuel Muñoz, lead author of the a new study and a researcher studying hydrologic and climatic variability at Northeastern University. “But if we don't, then these low water levels that ...
Flash Joule heating lights up lithium extraction from ores
2025-10-07
A new one-step, water- acid- and alkali-free method for extracting high-purity lithium from spodumene ore has the potential to transform critical metal processing and enhance renewable energy supply chains. This study is set to be published in Science Advances Oct. 3, 2025.
As the demand for lithium continues to rise, particularly for use in electric cars, smartphones and power storage, current extraction methods are struggling to keep pace. Extracting lithium from salty water is a lengthy process, and traditional methods that use heat and chemicals ...
COMBINEDBrain and MUSC announce partnership to establish biorepository for pediatric cerebrospinal fluid and CNS tissue bank
2025-10-07
Nashville, TN – COMBINEDBrain, a leader in advancing translational neuroscience research, and the Medical University of South Carolina (MUSC), one of the nation's premier academic health centers, are excited to announce a strategic partnership to establish a cutting-edge biorepository for pediatric central nervous system (CNS) tissue and biofluids. This collaborative effort, led by MUSC’s Dr. Ramin Eskandari and COMBINEDBrain’s Dr. Anna Pfalzer, aims to accelerate the development of treatments for neurological diseases and significantly aid drug companies in biomarker discovery and therapeutic development.
The biorepository will house ...